Multinational, multicentre, non-interventional study, in patients with rheumatoid arthritis (RA) treated with tocilizumab (ACT-UP)

Study identification

• EU PAS number:
  EUPAS9834
• Study ID:
  17512
• Official title and acronym:
  Multinational, multicentre, non-interventional study, in patients with rheumatoid arthritis (RA) treated with tocilizumab (ACT-UP)
• DARWIN EU® study:
  No
• Study countries:
  Costa Rica

  Dominican Republic

  Guatemala

  Panama
• Study description:
  This multicenter, observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in routine clinical practice in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment in accordance with the local label will be followed for 6 months.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual:01/10/2013

Study start date

Actual:08/10/2013

Data analysis start date

Actual:02/06/2014

Date of final study report

Planned:30/06/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Roche Central America and the Caribbean

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable